For Elfin, the sale of branded formulations in India is an integral part of business operations, which contributed little over 35% to the company’s sales income for FY 2013. India is one of the fastest growing pharmaceutical markets in the world, it is a major growth driver for the company.
Company’s clear focus on specialty segments of Ophthalmology, Dermatology, and Cardiovascular has enabled it to continue to grow at much higher rates over industry average growth rate of the Indian Pharmaceutical Market (IPM) for last 5 years. Our competency in identifying unmet medical needs and then being first-to-market many products has been our foundation for success throughout these years and will continue to be so in the coming years.
Language Translate »